150 mg/ml
Trade Name
HYMPAVZI
Solution for injection in pre-filled pen
Request Type
Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Marstacimab is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:
·severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
·severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.
·severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
·severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.